Telegraph Hill Partners

Total investments

40

Average round size

15M

Portfolio companies

27

Rounds per year

1.74

Lead investments

14

Follow on index

0.30

Exits

11

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsManufacturingMedical DeviceMedicalDeveloper PlatformLife ScienceAlternative Medicine

Summary

The leading representative office of defined VC is situated in the San Francisco. The venture was found in North America in United States.

The fund has specific favorite in a number of founders of portfolio startups. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Analytics, Developer Platform. Among the most popular portfolio startups of the fund, we may highlight LDR Holding, BioVentrix, AltheaDx. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.

Considering the real fund results, this VC is 36 percentage points more often commits exit comparing to other organizations. The higher amount of exits for fund were in 2013. The common things for fund are deals in the range of 10 - 50 millions dollars. This Telegraph Hill Partners works on 1 percentage points less the average amount of lead investments comparing to the other organizations. When the investment is from Telegraph Hill Partners the average startup value is 10-50 millions dollars. The fund is constantly included in less than 2 deals per year. The high activity for fund was in 2007. Despite it in 2019 the fund had an activity.

The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Telegraph Hill Partners, startups are often financed by Psilos Group, Waveland Venture Partners, Versant Ventures. The meaningful sponsors for the fund in investment in the same round are Saints Capital, Psilos Group, 5AM Ventures. In the next rounds fund is usually obtained by Saints Capital, Waveland Venture Partners, Tullis Health Investors.

The fund was created by John W. Watkins, Thomas A. Raffin. The overall number of key employees were 7.

Show more

Investments analytics

Analytics

Total investments
40
Lead investments
14
Exits
11
Rounds per year
1.74
Follow on index
0.30
Investments by industry
  • Biotechnology (25)
  • Health Care (23)
  • Medical (14)
  • Medical Device (13)
  • Manufacturing (10)
  • Show 30 more
Investments by region
  • United States (36)
  • Canada (2)
  • United Kingdom (1)
Peak activity year
2007
Number of Unicorns
1
Number of Decacorns
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
13
Avg. valuation at time of investment
74M
Group Appearance index
0.60
Avg. company exit year
13
Avg. multiplicator
3.17
Strategy success index
0.50

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Argonaut Manufacturing Services 05 Mar 2024 Biotechnology, Manufacturing, Life Science Early Stage Venture 45M United States, California, Carlsbad
Precision NanoSystem 29 Sep 2015 Biotechnology, Health Care, Genetics, Pharmaceutical Early Stage Venture 13M Canada, Vancouver, British Columbia
WhiteGlove Health 18 Mar 2009 Health Care, Wellness, Medical Early Stage Venture 2M United States, Texas, Austin

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.